Form 4: Alto Neuroscience CFO Sells Shares
Insider Transaction (Form 4)
Nicholas Conrad Smith, PRESIDENT AND CFO of Alto Neuroscience, Inc., sold 134,886 shares of common stock on September 29, 2026.
Summary
- Option exercise/conversion: acquired 56,455 Common Stock at $2.35 ($132,669) on September 29, 2026; holds 80,515 after (Direct).
- Option exercise/conversion: acquired 54,375 Common Stock at $2.35 ($127,781) on September 29, 2026; holds 134,890 after (Direct).
- Open-market sale: disposed of 110,830 Common Stock at $26.58 ($2,946,150) on September 29, 2026; holds 24,060 after (Direct).
- Option exercise/conversion: acquired 24,056 Common Stock at $2.35 ($56,532) on September 30, 2026; holds 48,116 after (Direct).
- Open-market sale: disposed of 23,170 Common Stock at $25.78 ($597,290) on September 30, 2026; holds 24,946 after (Direct).
- Open-market sale: disposed of 886 Common Stock at $26.87 ($23,807) on September 30, 2026; holds 24,060 after (Direct).
- Option exercise/conversion: disposed of 56,455 Employee Stock Option (Right to Buy) on September 29, 2026; holds 145,874 after (Direct).
- Option exercise/conversion: disposed of 54,375 Employee Stock Option (Right to Buy) on September 29, 2026; holds 35,625 after (Direct).
- Option exercise/conversion: disposed of 24,056 Employee Stock Option (Right to Buy) on September 30, 2026; holds 121,818 after (Direct).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $3,567,247 of stock on the open market.
Insider Transactions
Nicholas Conrad Smith — Officer (PRESIDENT AND CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-29 | Option exercise/conversion | Common Stock | 56,455 | $2 | $132.7K | 80,515 |
| 2026-09-29 | Option exercise/conversion | Common Stock | 54,375 | $2 | $127.8K | 134,890 |
| 2026-09-29 | Open-market sale | Common Stock | 110,830 | $27 | $2.9M | 24,060 |
| 2026-09-30 | Option exercise/conversion | Common Stock | 24,056 | $2 | $56.5K | 48,116 |
| 2026-09-30 | Open-market sale | Common Stock | 23,170 | $26 | $597.3K | 24,946 |
| 2026-09-30 | Open-market sale | Common Stock | 886 | $27 | $23.8K | 24,060 |
| 2026-09-29 | Option exercise/conversion | Employee Stock Option (Right to Buy) | 56,455 | — | — | 145,874 |
| 2026-09-29 | Option exercise/conversion | Employee Stock Option (Right to Buy) | 54,375 | — | — | 35,625 |
| 2026-09-30 | Option exercise/conversion | Employee Stock Option (Right to Buy) | 24,056 | — | — | 121,818 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-29 | Option exercise/conversion (56,455 shares) |
| 2026-09-29 | Option exercise/conversion (54,375 shares) |
| 2026-09-29 | Open-market sale (110,830 shares) |
| 2026-09-30 | Option exercise/conversion (24,056 shares) |
| 2026-09-30 | Open-market sale (23,170 shares) |
| 2026-09-30 | Open-market sale (886 shares) |
| 2026-09-29 | Option exercise/conversion (56,455 shares) |
| 2026-09-29 | Option exercise/conversion (54,375 shares) |
| 2026-09-30 | Option exercise/conversion (24,056 shares) |
Keywords
insider transaction, Form 4, ANRO, Alto Neuroscience, Inc., bearish, Nicholas Conrad Smith
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.